CD52
| Official symbol: | CD52 |
| Full name: | CD52 molecule |
| Location: | 1p36.11 |
| Also known as: | EDDM5, HE5, CDW52 |
| Entrez ID: | 1043 |
| Ensembl ID: | ENSG00000169442 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
| Expression restricted in 2 cancer type(s) | |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.00 | | Gscore (Del): | 0.40 |
|
|
|
| Recurrently deleted in 3 cancer type(s) |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | 2 |
|
|
| Fusions detected in 2 cancer type(s) |
|
| |
|
|
|
| Functional class: | Not specified |
| JensenLab PubMed score: | 551.06 (Percentile rank: 91.57%) |
| PubTator score: | 487.03 (Percentile rank: 93.17%) |
| Target development/druggability level: | TclinThese targets have activities in DrugCentral (ie. approved drugs) with known mechanism of action. |
| Tractability (small molecule): | N/A |
| Tractability (antibody): | Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets |
